Home > Riviste > Minerva Endocrinologica > Fascicoli precedenti > Minerva Endocrinologica 2018 June;43(2) > Minerva Endocrinologica 2018 June;43(2):198-211

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

REVIEW   

Minerva Endocrinologica 2018 June;43(2):198-211

DOI: 10.23736/S0391-1977.17.02753-5

Copyright © 2017 EDIZIONI MINERVA MEDICA

lingua: Inglese

Post-transplant diabetes: diagnosis and management

Brian P. BOERNER 1 , Vijay SHIVASWAMY 1, 2, Eric WOLATZ 3, Jennifer LARSEN 1

1 Division of Diabetes, Endocrinology, and Metabolism, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA; 2 VA Nebraska-Western Iowa Health Care System, Omaha, NE, USA; 3 College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA


PDF


Post-transplant diabetes mellitus (PTDM) is common after most types of solid organ transplantation, though the actual incidence is as yet unknown because of the use of different diagnostic criteria. PTDM is the result of individual risk factors as well as risk factors associated with the transplant itself, particularly immunosuppressants. Previously called New Onset Diabetes, in many cases inadequate screening for diabetes before transplant cannot assure that the diabetes is new after transplant. The most recent international consensus guidelines suggest diagnosis should be delayed until the patient is taking maintenance doses of immunosuppressants even if they require treatment in the immediate hospitalization. Criteria for diagnosis follow those of the American Diabetes Association and the World Health Organization, although hemoglobin A1C should not be used as the only screening test at least until one year after transplant because of its insensitivity for significant glucose intolerance in the transplant patient and setting. Management of PTDM is best done in a team setting, with an emphasis on glycemic control, dyslipidemia, and hypertension, and taking into consideration immunosuppressant regimens and potential drug side effects and interactions. While PTDM has been associated with changes in outcomes, these have and may continue to improve with improved diabetes care in and out of the hospital, and other changes in post-transplant care.


KEY WORDS: Transplantation - Diabetes mellitus - Immunosuppressive agents - Renal insufficiency

inizio pagina